▷ LFB and Kedrion sign industrial collaboration agreement to…

31.01.2022 – 17:52

Kedrion Biopharma

Les Ulis, France and Lucca, Italy, March 12, 2019 /PRNewswire/

Two leading European pharmaceutical companies, LFB and Kedrion, are joining forces in an industrial collaboration agreement to improve the availability of plasma-derived medicine, immunoglobulin, to patients in France.

As part of this industrial partnership, Kedrion will produce immunoglobulins in Hungary from LFB plasma collected in France by Etablissement Français du Sang. These immunoglobulins, manufactured by Kedrion, are imported by LFB in France and complement LFB’s own immunoglobulins, which are made available to hospitals in France in consultation and under the control of the French health authorities.

I am very pleased about this partnership with Kedrion, which will allow us to meet the growing needs of the French market for immunoglobulins, which are in high demand both in France and worldwide become,” stressed Denis Delval, President and CEO of LFB. „Our agreement with Kedrion will allow us to provide additional supplies of immunoglobulins to patients in France.

Paolo Marcucci, President of Kedrion, said: “I welcome the collaboration agreement with LFB as it represents a solution for patients in France.” Mr Marcucci added: “Kedrion shares LFB’s values ​​and raison d’être, which is to provide products and therapies for patients with serious and often rare diseases.

About Kedrion Biopharma

Kedrion Biopharma is a biopharmaceutical company that collects and fractionates plasma to manufacture and market worldwide plasma-derived products for the prevention and treatment of rare and debilitating diseases and conditions such as hemophilia, primary immunodeficiency disorders and RH sensitization.

Kedrion is headquartered in Tuscany and employs more than 2,800 people worldwide. The company is present in 100 countries and is the fifth largest operator in the world and the first in Italy. Kedrion has manufacturing facilities in Italy, Hungary and North America, and its subsidiary KEDPLASMA operates plasma collection centers in the United States.

About LFB

LFB is a biopharmaceutical company that develops, manufactures and markets plasma-derived medicines and recombinant proteins for the treatment of patients with serious and often rare diseases. Founded in France in 1994, LFB is now one of Europe’s leading providers of blood-derived medicines for healthcare, with a mission to create new treatment options for patients in three key therapeutic areas: immunology, hemostasis and critical care.

Photo – https://mma.prnewswire.com/media/1736226/Kedrion_Paolo_Marcucci.jpg

Logo – https://mma.prnewswire.com/media/1736227/Kedrion_Biopharma_Logo.jpg

Logo – https://mma.prnewswire.com/media/1736228/LFB_Logo.jpg

Press contact:

Lisa Nordio,
[email protected],
+39 348 6559718

Original content from: Kedrion Biopharma, transmitted by news aktuell


Leave a Reply

Your email address will not be published.